Catalyst Wire Dossier Catalyst Wire Dossier

Acoramidis

acoramidis · Eidos Therapeutics, a BridgeBio company
Drug timelines are a Plus or Pro feature.

8 regulatory and trial events tracked for Acoramidis, covering 2024-09-19 to 2026-04-06. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis [Phase 4]

See pricing